To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE